These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 29908836

  • 1. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
    Karaboyas A, Xu H, Morgenstern H, Locatelli F, Jadoul M, Nitta K, Dasgupta I, Tentori F, Port FK, Robinson BM.
    Kidney Int; 2018 Sep; 94(3):589-598. PubMed ID: 29908836
    [Abstract] [Full Text] [Related]

  • 2. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e012655. PubMed ID: 31711387
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.
    Chang TI, Zheng Y, Montez-Rath ME, Winkelmayer WC.
    Clin J Am Soc Nephrol; 2016 Aug 08; 11(8):1401-1412. PubMed ID: 27354656
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
    Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA.
    Am J Kidney Dis; 2003 Dec 08; 42(6):1260-9. PubMed ID: 14655199
    [Abstract] [Full Text] [Related]

  • 6. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 Dec 08; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
    Bakhai A, Palaka E, Linde C, Bennett H, Furuland H, Qin L, McEwan P, Evans M.
    J Med Econ; 2018 Dec 08; 21(12):1172-1182. PubMed ID: 30160541
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
    Fonseca C, Brito D, Branco P, Frazão JM, Silva-Cardoso J, Bettencourt P.
    Rev Port Cardiol (Engl Ed); 2020 Sep 08; 39(9):517-541. PubMed ID: 32868174
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators Group.
    Eur J Heart Fail; 2020 Aug 08; 22(8):1378-1389. PubMed ID: 32243669
    [Abstract] [Full Text] [Related]

  • 16. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL.
    J Am Heart Assoc; 2018 Oct 02; 7(19):e009992. PubMed ID: 30371331
    [Abstract] [Full Text] [Related]

  • 17. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
    Alsalemi N, Sadowski CA, Elftouh N, Louis M, Kilpatrick K, Houle SKD, Lafrance JP.
    BMC Nephrol; 2022 Apr 28; 23(1):161. PubMed ID: 35484505
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH, Wang CC, Chen TH, Hong CY, Sue YM.
    J Am Heart Assoc; 2016 Jan 06; 5(1):. PubMed ID: 26738790
    [Abstract] [Full Text] [Related]

  • 19. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, Ceconi C, Coats AJS, Drexel H, Filippatos G, Kaski JC, Lund L, Niessner A, Ponikowski P, Savarese G, Schmidt TA, Seferovic P, Wassmann S, Walther T, Lewis BS.
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul 01; 4(3):180-188. PubMed ID: 29726985
    [Abstract] [Full Text] [Related]

  • 20. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
    Wang AY.
    Nephrol Dial Transplant; 2019 Dec 01; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.